SMTL Blog

SMTL are pleased to formally welcome two new members of staff to the team.

Chloe Parry joins our office team to cover maternity leave.  Chloe has worked in various office administration roles in a number of local companies and joined the Office team at SMTL in February 2020.

Lisa Tully joins the SMTL Biologial team on a research project investigating methods of measuring residual protein on surgical instruments. With a BSc in Biomedical Science and a Master’s degree in Integrative Bioscience and Business,   Lisa has worked for several research based companies, most recently for Jellagen, a marine biotechnology company who develop scientific products based on collagen, including Jellyfish collagen. Lisa also started in February 2020.

Finally, we said goodbye to Angela Clarke,  who retired from SMTL in November.  We would like to thank Angela for her hard work, diligence and loyalty since she started in SMTL and send her and her husband Mike our best wishes for the future.

 

 

 

 

 

Dr James Evans, a healthcare researcher at SMTL, has had a  paper published in Applied Health Economics and Health Policy  (Dale, M., Evans, J., Carter, K., O’Connell, S., Morgan, H., Carolan-Rees, G., 2019. iFuse Implant System for Treating Chronic Sacroiliac Joint Pain: A NICE Medical Technology Guidance. Appl Health Econ Health Policy. https://doi.org/10.1007/s40258-019-00539-7).

James carried out the work whilst working at Cedar. The paper presents the process undertaken for the development of National Institute for Health and Care Excellence (NICE) Medical Technology Guidance on iFuse, an implant for the treatment of chronic sacroiliac joint pain.

Clinical results suggested that iFuse led to improved pain, improved Oswestry disability index (ODI) and improved quality of life when compared to non-surgical treatment. The economic analysis indicated that iFuse becomes cost saving at 8 years (approximately £129 per patient) compared to non-surgical treatments and that these cost savings continue to increase after 8 years. NICE published guidance in October 2018 recommending that the case for adoption of the iFuse system in the UK National Health Service (NHS) was supported by the evidence

 

Leanne Gater, a documentary film maker from Wild Films contacted SMTL earlier this year about a documentary project on Horseshoe Crabs.  SMTL undertake endotoxin testing for NHS facilities across Wales using  LAL, a substance derived from the blood of these Horseshoe Crabs.

Leanne wanted to to demonstrate how Horseshoe Crabs aid in keeping millions of people safe though endotoxin testing, but also how they’re also suffering from a decline in population and what could be done to help save the species.

Endotoxins are complexes associated with the outer membrane of Gram-negative bacteria which are constantly shed into the environment and released when the bacteria die or multiply. Bacterial endotoxins are the most common and by far the most potent pyrogen (pyrogen literally means heat generating, and the term refers to any substance, microbial or otherwise, which would induce a temperature rise when introduced into a patient). Commonly used methods of sterilisation generally do not destroy endotoxins, therefore a product may be sterile and free of viable microorganisms but not necessarliy be endotoxin-free.

Leanne spent time at SMTL in October 2019 and filmed SMTL staff undertaking the tests which we perform for Health Boards across Wales, checking that their surgical instruments have been reprocessed appropriately and that there is no unsafe level of residual endotoxin on their instrument. 

We will update this page when we know the date of release of Leanne's film.

 

SMTL have recently published and updated three articles on medical compression hosiery:

 

The Evidence Based Procurement Board have published their latest advice which is on Farco-fill protect, a sterile solution containing 0.3% triclosan that is used for the inflation of indwelling urinary catheters in an effort to reduce bacterial colonisation of the catheter

Following consideration of the published evidence, the EBPB consider that there is currently insufficient evidence to support its use in the Welsh NHS.  Read the full review on the EBPB web site.

More Articles...

Joomla Templates: from JoomlaShack